NCT04644003View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

January 28, 2022

Study Completion Date

January 28, 2022

Conditions

Autism Spectrum Disorder

Interventions

DRUG

STP1

STP1 is a combination of two drugs, a phosphodiesterase (PDE) inhibitor and an NKCC1 inhibitor

DRUG

Placebo

Placebo medication (capsule and tablet) identical in appearance to active medication

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors

lead

Stalicla SA

INDUSTRY

NCT04644003 - Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD) | Biotech Hunter | Biotech Hunter